EDUARDO MATOS

Dr. EDUARDO MATOS

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2023 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
MMMoisés Sihuincha Maldonado
Moisés Sihuincha Maldonado
ALAldo Javier Lucchetti
Aldo Javier Lucchetti
RPRaisa Alessandra Paredes Pacheco
Raisa Alessandra Paredes Pacheco
LCLeonel Christian Martínez Cevallos
Leonel Christian Martínez Cevallos
ESEnrique Uless Zumaeta Saavedra
Enrique Uless Zumaeta Saavedra
EDUARDO MATOSEDUARDO MATOS
EDUARDO MATOS
Monkeypox (Mpox) recent outbreak has changed in terms of predominant transmission route and typical presentation. Describing current epidemiological and clinical characteristics is crucial to identifying cases and halting transmission. An observational study was conducted at a Peruvian tertiary-level hospital and included all individuals with Mpox virus infection between July 01 and September 03, 2022. Among 205 confirmed cases, 99% (202/205) were men, 94% (192/205) were men who have sex with men or bisexual, and 66% (136/205) were living with HIV. Regarding sexual behavior, 87% (179/205) had a sexual encounter 21 days before consultation, although only 8% (17/205) identified sexual contact with a Mpox confirmed case; 65% (133/205) had sexual intercourse with casual partners, 55% (112/205) reported a last sexual partner unknown, and 21.5% (44/205) continued having sexual intercourse with symptoms. Systemic symptoms were fever (162/205, 79%), malaise (123/205, 60%), headache (119/205, 58%), fatigue (105/205, 52%), and lymphadenopathy (111/205, 54%). The distribution of skin lesions was generalized (166/205, 81%), located in the anogenital area (160/205, 78%), polymorphic (174/205, 85%), and it was the first symptom identified in 46% (94/205) of cases. Overall, 10% (21/205) required hospitalization, of whom 85.7% (18/205) have HIV infection. Complications included bacterial superinfection (n = 18), proctitis (n = 6), balanitis (n = 4), and necrosis of skin lesions (n = 3). In 2022, Mpox mainly affects men who have sex with men and People living with HIV/AIDS. It presents with skin lesions localized to the anogenital area and can lead to severe complications requiring hospitalization.

7 October 2023 in Journal of Adolescent Health
Verified
Journal Article
Open access
MNMiyu Niwa
Miyu Niwa
EDUARDO MATOSEDUARDO MATOS
EDUARDO MATOS
CRCarly Rodriguez
Carly Rodriguez
MWMilagros Wong
Milagros Wong
RERenato A. Errea
Renato A. Errea
MFMolly Franke
Molly Franke
Published data on outcomes among adolescents newly initiating antiretroviral treatment in the Latin American context are sparse. We estimated the frequency of sustained retention with viral load suppression (i.e., successful transition) and identified predictors of successful transition into adult care among youth (aged 14-21 years) with recently acquired HIV in Lima, Peru. A retrospective cohort study was conducted among 184 adolescents and young adults who initiated antiretroviral therapy in an adult public sector HIV clinic between June 2014 and June 2019. Sustained retention (no loss-to-follow-up or death) with viral suppression was calculated for the first 12 and 24 months following treatment initiation. We conducted regression analyses to assess factors associated with successful transition to adult HIV care, including gender, age, occupation, nationality, pregnancy, same-sex sexual behavior, presence of treatment supporter, number of living parents, and social risk factors that may adversely influence health (e.g., lack of social support, economic deprivation). Patients were predominantly male (n = 167, 90.8%). Median age was 19 years (interquartile range: 18-21). Frequency of sustained retention with viral load suppression was 42.4% (78/184) and 35.3% (30/85) at 12 and 24 months following treatment initiation. In multivariable analyses, working and/or studying was inversely associated with successful transition into adult care at 12 months; number of known living parents (relative risk: 2.20; 95% confidence interval: 1.12, 4.34) and absence of social risk factors (relative risk: 1.68; 95% confidence interval: 0.91, 3.11) were positively associated with successful transition at 24 months. Sustained retention in HIV care was uncommon. Parental support and interventions targeting social risk factors may contribute to successful transition into adult HIV care in this group.

10 June 2022 in Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
Verified
Journal Article
Open access
PDF file
JHJorge Hurtado-Alegre
Jorge Hurtado-Alegre
LCLuis Enrique Carrasco-Lozano
Luis Enrique Carrasco-Lozano
JZJuliana Zavala-Portugal
Juliana Zavala-Portugal
JQJhosef Franck Quispe-Pari
Jhosef Franck Quispe-Pari
EDUARDO MATOSEDUARDO MATOS
EDUARDO MATOS
Introducción: La infección por el virus del dengue es una enfermedad endémica en ciertas regiones del Perú. La mayoría de estos casos se clasifican como dengue sin signos de alarma y la mortalidad reportada es menor de 1%. Sin embargo, existen ciertas condiciones asociadas a la enfermedad que podrían incrementar la mortalidad. Reporte de caso: Se presenta el caso de una paciente mujer de 48 años procedente de área endémica de esta infección con cuadro clínico y hallazgos laboratoriales compatibles con enfermedad por dengue con signos de alarma. Durante la hospitalización, cursa con hemoptisis e insuficiencia respiratoria produciendo su posterior fallecimiento. Conclusión: Es importante reconocer la hemorragia alveolar difusa como parte del compromiso respiratorio por dengue y diferenciarlo de otras posibilidades infecciosas y no infecciosas para poder brindar el manejo adecuado de forma temprana.

10 February 2025 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
GSGiselle Soto
Giselle Soto
CRCandice Romero
Candice Romero
MGMiriam Gonzales
Miriam Gonzales
SRSayda La Rosa
Sayda La Rosa
DPDiana Ponce
Diana Ponce
JNJoan Neyra
Joan Neyra
Vaccinating healthcare personnel (HCP) is a top priority for public health globally. This strategy aims not only to protect HCP but also patients, reducing transmission of infections in healthcare services. However, improving vaccine coverage in HCP is still a challenge, especially because they are a risk group for acquiring influenza. Multicomponent influenza vaccination programs targeting behavioral, organizational, and administrative barriers are critical to ensure this priority population is vaccinated. Here, we describe a healthcare worker cohort study that was implemented in Peru, a middle-income country, in 2016, prior to the coronavirus disease 2019 pandemic. This cohort, which is still ongoing, has collected valuable information on influenza vaccine effectiveness, vaccine coverage, risk factors, absenteeism, and use of personal protective equipment, as well as risk of influenza disease, among others. These data can help improve knowledge not only about influenza diseases but also regarding vaccination on this specific influenza risk group in order to improve vaccine uptake.

6 May 2026 in medRxiv
Verified
Preprint
Open access
PDF file
SRSamara Ruberg
Samara Ruberg
ANAlyson Nunez
Alyson Nunez
MWMilagros Wong
Milagros Wong
MCMarguerite Curtis
Marguerite Curtis
YSYihan Shi
Yihan Shi
MFMolly Franke
Molly Franke
Background: Stigma remains a pervasive barrier to curbing the spread of human immunodeficiency virus (HIV) among adolescents and young adults in Lima, Peru. Social media offers a promising avenue for scalable, youth-centered stigma reduction, but few interventions have been rigorously evaluated in this context. Objective: We evaluated the potential of a social media campaign to reduce perceived HIV-related stigma among young adults living with HIV. This involved a sequential explanatory mixed-methods study, including a randomized evaluation, followed by focus groups to understand the findings. Methods: 150 young adults (aged 18-29 years) living with HIV (YLWH) were randomized to receive information on social media from one of the following: (1) the control account; (2) the control account and the social media campaign accounts (Instagram and TikTok); or (3) the control account, the campaign accounts, and the accounts of participating influencers. Perceived stigma was measured via pre- and post-campaign surveys using Spanish versions of the abridged Berger HIV Stigma Scale and the Stigma Stress Scale. Focus groups and interviews were conducted with a purposive sample of participants to contextualize quantitative results. Qualitative data were analyzed using Framework Analysis. Results: Mean changes in HIV Stigma and Stigma Stress scores were small and not statistically significant. Post-hoc as-treated analyses supported these findings. Fidelity to intervention allocation was low to moderate, depending on the metric considered. Qualitative data suggested that the campaign positively impacted participants’ perceived stigma and that personal circumstances, crossover, frequency of exposure to content, and issues related to completing study questionnaires contributed to the lack of meaningful change in stigma scores. Conclusions: While quantitative data did not support that exposure to a social media campaign led to meaningful reductions in HIV-related stigma, qualitative data suggested that the campaign had a positive impact and that limitations in the study design, together with external factors, may have obscured benefits in quantitative analyses.

30 May 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
CSClara Suñer
Clara Suñer
RERoser Escrig-Sarreta
Roser Escrig-Sarreta
CGCristina Galvan
Cristina Galvan
EDUARDO MATOSEDUARDO MATOS
EDUARDO MATOS
AGAmanda Gabster
Amanda Gabster
RGREMAIN Study Group
REMAIN Study Group
Background: The MVA-BN vaccine is considered effective for preventing mpox in key populations, based on observational studies, though no randomized trials have yet confirmed its effectiveness. Observational studies published to date rely on retrospective analyses of routine data, often missing information on relevant risk factors for mpox. Methods: Multi-country target trial emulation study with prospective data collection. Between 1 September 2022 and 15 June 2023, we recruited individuals eligible for mpox vaccination based on clinical history and exposure behaviors via healthcare centers and social venues in Spain, Peru, Panama, and Chile. Vaccinated individuals were paired with unvaccinated counterparts matched by mpox risk factors, country, recruitment date, and age. Follow-up continued via periodic surveys until 31 March 2024. The primary endpoint was symptomatic mpox occurrence ≥14 days post-vaccination. Results: The primary analysis included 1028 individuals (514 vaccinated, 514 unvaccinated) with a median follow-up time of 9.3 months (IQR 4.7–13.7). Mpox occurred in eight participants (0.8%): three vaccinated and five unvaccinated (HR 0.6; 95% CI 0.21–1.70). Adverse reactions were reported by 731 (49.6%) participants, predominantly skin reactions (703/1475; 47.7%), while systemic reactions occurred in 107 (7.3%). Long-lasting erythema at the injection site was reported in 450/1058 (42.5%) participants, persisting >6 months in 107 of them (23.8%). Conclusions: The low incidence of mpox during the study period resulted in a limited number of endpoint events, precluding robust conclusions on the efficacy of the MVA-BN vaccine as pre-exposure prevention for mpox. However, our analysis, which accounted for key confounders such as exposure behaviors, yielded results consistent with previous studies suggesting the effectiveness of the vaccine in the mpox setting.